Unicycive Therapeutics, Inc. (UNCY)
About Unicycive Therapeutics, Inc.
Unicycive Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and commercializing therapies to address unmet medical needs, with a primary focus on kidney disease. The company is advancing two key product candidates: oxylanthanum carbonate (OLC), a phosphate binder for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis, and UNI-494, a drug candidate for the treatment of acute kidney injury.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2023
- $675.0K
- Net income
- -$26.6M
- Total assets
- $49.1M
- Market cap
- $184.8M
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $29.5M
- Operating income
- -$29.5M
- Net income
- -$26.6M
- EPS (basic)
- $-1.67
- EPS (diluted)
- $-1.67
Balance sheet
- Total assets
- $49.1M
- Current assets
- $49.0M
- Total liabilities
- $18.9M
- Current liabilities
- $18.9M
- Shareholders’ equity
- $30.2M
Cash flow
- Operating cash flow
- -$31.3M
- Investing cash flow
- -$12.1M
- Financing cash flow
- $46.5M
- Net cash flow
- $3.1M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $184.8M
- EPS (diluted)
- $-1.67
- Shares outstanding
- 34.2M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jul 13, 2021
Unicycive Therapeutics, Inc. (UNCY) Stock Price
- Reported a net loss of $26.6M in FY2023.
- Trading 37% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Unicycive Therapeutics, Inc..
Write a review
News about Unicycive Therapeutics, Inc.
News & sentiment via Polygon.io
Unicycive Therapeutics, Inc.: frequently asked questions
Is Unicycive Therapeutics, Inc. an American company?
Unicycive Therapeutics, Inc. is a US-based company headquartered in Mountain View, California, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is Unicycive Therapeutics, Inc. headquartered?
Unicycive Therapeutics, Inc. is headquartered in Mountain View, California, United States.
Is Unicycive Therapeutics, Inc. publicly traded?
Yes — Unicycive Therapeutics, Inc. is a publicly traded company. Its stock trades under the ticker symbol UNCY on the NASDAQ.
What does Unicycive Therapeutics, Inc. do?
Unicycive Therapeutics, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.
